Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication [Yahoo! Finance]
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer [Yahoo! Finance]
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News [Yahoo! Finance]
Neurocrine Biosciences to Present at Upcoming Investor Conferences